Trial reportIndian heart journal2018
Prophylactic use of carvedilol to prevent ventricular dysfunction in patients with cancer treated with doxorubicin.
Trial report in Indian heart journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06103279 (Evaluation of Empagliflozin Effect Against Doxorubicin Induced Cardiomyopathy), which is not on this map. Cited by 31 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of Empagliflozin Effect Against Doxorubicin Induced Cardiomyopathy
Who cites it
31 citing papers in PubMed, 6 syntheses or guidelines pooled it, 48 citations in OpenAlex.
- Is Carvedilol Effective in Preventing and Modulating Concentric Cardiac Remodelling? A Comprehensive Systematic Review and Meta-Analyses.Cardiovascular therapeutics · 2025Pooled it
- Renin-angiotensin System Antagonists and Beta-blockers in Prevention of Anthracycline Cardiotoxicity: a Systematic Review and Meta-analysis.Arquivos brasileiros de cardiologia · 2023Pooled it
- Preventive use of beta-blockers for anthracycline-induced cardiotoxicity: A network meta-analysis.Frontiers in cardiovascular medicine · 2022Pooled it
- Statins to mitigate cardiotoxicity in cancer patients treated with anthracyclines and/or trastuzumab: a systematic review and meta-analysis.Cancer causes & control : CCC · 2021Pooled it
- Prevention of anthracycline-induced cardiotoxicity: a systematic review and meta-analysis.Internal and emergency medicine · 2021Pooled it
- Heart failure from cancer therapy: can we prevent it?ESC heart failure · 2019Pooled it
- The efficacy of carvedilol in improving cardiac function and survival in patients with anthracycline-induced cardiotoxicity: a comprehensive systematic review and meta-analysis.International journal of cardiology. Heart & vasculature · 2026Article
- Protective effects of beta-blockers against anthracycline- and trastuzumab-related cardiotoxicity: a systematic review based on conventional and Bayesian network meta-analysis.Frontiers in cardiovascular medicine · 2026Review
- Prevention and treatment of anthracycline-induced cardiotoxicity: a systematic review and network meta-analysis of randomized controlled trials.Cardio-oncology (London, England) · 2025Review
- Cancer-Therapy-Related Cardiac Dysfunction: Latest Advances in Prevention and Treatment.Life (Basel, Switzerland) · 2025Review
- Beta-blockers for preventing anthracycline-induced cardiotoxicity: a systematic review with network meta-analysis.Revista da Associacao Medica Brasileira (1992) · 2025Article
- Efficacy and harms associated with β-blockers for cardiotoxicity in cancer patients undergoing chemotherapy: a systematic review and meta-analysis.Archives of medical science : AMS · 2025Review
- Role of Oxidative Stress and Inflammation in Doxorubicin-Induced Cardiotoxicity: A Brief Account.International journal of molecular sciences · 2024Review
- Prevention of Anthracyclines and HER2 Inhibitor-Induced Cardiotoxicity: A Systematic Review and Meta-Analysis.Cancers · 2024Review
- An update of the molecular mechanisms underlying anthracycline induced cardiotoxicity.Frontiers in pharmacology · 2024Review
- Review of cancer therapies for the perioperative physician.Perioperative medicine (London, England) · 2023Review
- Review
- Anthracycline-induced cardiotoxicity: mechanisms, monitoring, and prevention.Frontiers in cardiovascular medicine · 2023Review
- Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveDeterioration in ventricular function is often observed in patients treated with anthracyclines for cancer. There is a paucity of evidence on interventions that might provide cardio-protection. We investigated whether prophylactic use of carvedilol can prevent doxorubicin-induced cardiotoxicity and whether any observed effect is dose related.
methodsA prospective, randomized, double-blind study in patients treated with doxorubicin, comparing placebo (n = 38) with different doses of carvedilol [6.25 mg/day (n = 41), 12.5 mg/day (n = 38) or 25 mg/day (n = 37)]. The primary endpoint was the measured change in left ventricular ejection fraction (LVEF) from baseline to 6 months.
resultsLVEF decreased from 62 ± 5% at baseline to 58 ± 7% at 6-months (p = 0.002) in patients assigned to placebo but no statistically significant changes were observed in any of the 3 carvedilol groups. At 6 months, only one of 116 patients (1%) assigned to carvedilol had an LVEF < 50% compared to four of the 38 assigned to placebo (11%), (p = 0.013). No significant differences were noted between carvedilol and placebo in terms of the development of diastolic dysfunction, clinically overt heart failure or death.
conclusionsCarvedilol might prevent deterioration in LVEF in cancer patients treated with doxorubicin. This effect may not be dose related within the studied range.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.